Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-primaquine
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
R-primaquine (RPQ) is an enantiomer of primaquine, an antimalarial drug. It is being investigated in clinical trials to understand its comparative tolerability, metabolism, and pharmacokinetic behavior in healthy human volunteers and in individuals with G6PD deficiency. These studies aim to evaluate RPQ's properties alongside S-primaquine (SPQ) and the racemic mixture (RSPQ).
- Other names
- Primaquine enantiomer
02
Targets
Reactive oxygen species-sensitive iron-sulfur cluster-containing proteins
Beyond the preview
Go deeper on R-primaquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-primaquine.